# MTP-131 bij reperfusieschade na STEMI: de EMBRACE STEMI fase-2a-trial

*geplaatst 2016-04-21 · Algemeen · European heart journal · doi 10.1093/eurheartj/ehv597 · https://hartvaat.nl/2016/04/21/mtp-131-bij-reperfusieschade-na-stemi-de-embrace-stemi-fase-2a-trial/*

Fase 2a-trial van intraveneus MTP-131, een mitochondriaal gericht peptide, voor beperking van reperfusieschade bij STEMI. Onderzocht een nieuw mechanisme voor myocardprotectie tijdens primaire PCI.

## English: EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention.

The EMBRACE STEMI phase 2a trial tested MTP-131 (elamipretide), a mitochondria-targeted peptide, for limiting reperfusion injury after STEMI, exploring subcellular cardioprotection during primary PCI.

## Abstract (original, from the publication)

AIMS: Among patients with ST-elevation myocardial infarction (STEMI), reperfusion injury contributes to additional myocardial damage. MTP-131 is a cell-permeable peptide that preserves the integrity of cardiolipin, enhances mitochondrial energetics, and improves myocyte survival during reperfusion. METHODS AND RESULTS: EMBRACE STEMI is a multicentre, randomized, double-blind Phase 2a trial that evaluated the efficacy and safety of MTP-131 vs. placebo infused at a rate of 0.05 mg/kg/h for 1 h among first-time anterior STEMI subjects undergoing primary percutaneous coronary intervention (PCI) for a proximal or mid left anterior descending (LAD) artery occlusion. Administration of MTP-131 was not associated with a significant reduction in the primary endpoint, infarct size by creatine kinase-myocardial band (CK-MB) area under the curve (AUC) over 72 h (5785 ± 426 ng h/mL in placebo vs. 5570 ± 486 ng h/mL in MTP-131; ITALIC! P = NS). MTP-131 was not associated with an improvement in pre-specified magnetic resonance imaging, angiographic, electrocardiographic, or clinical outcomes. CONCLUSION: Among subjects with first-time anterior STEMI due to a proximal or mid LAD lesion who undergo successful PCI, administration of MTP-131 was safe and well tolerated. Treatment with MTP-131 was not associated with a decrease in myocardial infarct size as assessed by AUC0-72 of CK-MB.

Auteurs: C Michael Gibson, Robert P Giugliano, Robert A Kloner, Christoph Bode, Michal Tendera, András Jánosi, Bela Merkely, Jacek Godlewski, Rim Halaby, Serge Korjian, Yazan Daaboul, Anjan K Chakrabarti, Kathryn Spielman, Brandon J Neal, W Douglas Weaver

---
Bron: European heart journal, https://doi.org/10.1093/eurheartj/ehv597. Bijgewerkt 2026-07-03T13:25:25Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.